Nilson

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nilson

Property Description
Active Ingredient Ceftriaxone sodium
Form Lyophilized powder for solution
Pharmacological Class Third-generation cephalosporin antibiotic
General Use Treating systemic bacterial infections
Origin Semisynthetic compound

What Type of Antibiotic is Nilson?

Nilson is a powerful prescription-only medicine whose active ingredient is Ceftriaxone, a third-generation cephalosporin antibiotic. This classification places the drug within the broader category of β-lactam antibiotics, a class clinically recognized for their efficacy against a wide range of bacteria. Ceftriaxone is recognized as a broad-spectrum, bactericidal agent. This semisynthetic compound, derived from a natural substance but chemically modified, is widely used globally under various trade names, making Ceftriaxone one of the most recognized injectable antibiotics. As a single active ingredient product, Nilson concentrates its therapeutic potential solely on the established bactericidal mechanism of Ceftriaxone.


Understanding the Drug's Form and General Purpose

Nilson is supplied as a sterile lyophilized powder (Ceftriaxone sodium) that must be reconstituted with a sterile liquid diluent immediately before administration. This type of injectable presentation is critical for ensuring reliable systemic drug levels. This unique parenteral route of administration, typically through intramuscular injection or intravenous infusion, is a key distinguishing factor that supports its use in serious infections. Its general purpose is rooted in its bactericidal action, where it swiftly kills susceptible bacteria by interfering with their ability to build and maintain their protective cell wall. This mode of operation makes Nilson a broad-spectrum agent, offering the critical benefit of quickly controlling serious bacterial threats that require high, predictable concentrations of medicine in the bloodstream.

Regulatory References

  1. Ceftriaxone - LiverTox - NIH
  2. Ceftriaxone for Injection - DailyMed (FDA)

What side effects are possible with Nilson?

Possible Side Effects and Safety Information

Regulatory documentation structures the safety profile of this medicine by classifying adverse reactions and identifying clinically significant events that require close medical monitoring. The information provided below is based on the official governmental safety labels.

Clinically Significant and Serious Adverse Reactions

Two serious and potentially fatal adverse reactions have been documented in regulatory sources and require immediate attention and specific monitoring:

  • Interstitial Pneumonitis: This rare but serious reaction involves inflammation of the lung tissue. Symptoms can include fever, cough, chest pain, or difficulty breathing (exertional dyspnea). Patients should be instructed to report any new or worsening respiratory issues immediately.
  • Severe Liver Injury (Hepatitis): Rare cases of liver injury, including those resulting in death or hospitalization, have been reported, typically within the first few months of treatment. Liver function tests must be monitored regularly, and the drug should be discontinued if jaundice or significant elevations in liver enzymes occur.

Common and Other Adverse Reactions

Adverse reactions that were commonly reported in clinical trials across various system-organ classes include:

  • Nervous System: A frequent reaction is a delay in adaptation to the dark when transitioning from a bright to a dim area.
  • Metabolic: Intolerance to alcohol is reported in approximately 5% of patients, characterized by facial flushing, malaise, and a drop in blood pressure following alcohol ingestion.
  • Gastrointestinal: Common events include hot flashes, nausea, constipation, and vomiting.

Safety Restrictions and Monitoring Notes

The medicine is formally contraindicated in patients with severe hepatic impairment; baseline liver enzymes must be assessed before starting treatment. Ongoing monitoring of liver function is mandatory. Additionally, the possibility of interstitial pneumonitis requires patients to be monitored for pulmonary symptoms.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Nilson is a medical emergency that requires immediate medical attention. The most dangerous consequence of overdose with this class of medication is respiratory depression (severely slowed or stopped breathing), which can be life-threatening.

Overdose is associated with an excessive amount of the substance in the body and may be compounded by the simultaneous use of other central nervous system (CNS) depressants, such as alcohol or benzodiazepines. This combination significantly increases the risk of serious outcomes, including fatality.

Documented Clinical Manifestations

Signs of a potential overdose include:

  • Severely depressed level of consciousness (ranging from profound lethargy to coma).
  • Respiratory distress (slow, shallow, or stopped breathing).
  • Miosis (pinpoint pupils), though this is not always present.
  • Cold and clammy skin and limp body.
  • Blue or purple discoloration of the lips or fingernails (a sign of low oxygen).

Required Emergency Action

If an overdose is suspected, call emergency medical services immediately.

If available and properly trained, a rapid-acting opioid antagonist (such as naloxone) should be administered as part of the emergency response protocol. The patient must be closely monitored, as the effects of the reversal agent may wear off, leading to re-narcotization. Hospitalization is necessary for comprehensive medical evaluation and ongoing supportive care.

Therapeutic Uses of Nilson

Nilson's active ingredient, Ceftriaxone, is considered relevant in managing various conditions presenting with systemic or localized discomfort caused by bacteria. This medication is applied in addressing severe conditions like meningitis (CNS infection), septicemia, severe pneumonia, and complicated pelvic inflammatory disease.

This therapeutic area may assist with managing symptoms related to systemic imbalance, such as high fever and acute organ distress, and is commonly used across conditions presenting with acute or disruptive episodes. For instance, it is applied in clinical settings that involve acute or unstable symptom patterns, assisting with maintaining functional stability.

“This medication provides support that helps ease the overall symptom burden in situations where patients experience noticeable physiological strain.”


Quick Fact: Relief for Systemic Discomfort

Nilson is relevant for easing symptoms that create noticeable physiological strain. It is used in scenarios where additional management of discomfort is required. This assists with maintaining functional stability during conditions marked by increased physiological stress.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Nilson?

The population eligibility for Nilson (Ceftriaxone) is defined by official regulatory documentation, establishing clear restrictions based on allergic history, age, and specific physiological conditions.


Contraindicated Populations

Nilson is contraindicated and must not be used in patients with a history of hypersensitivity to ceftriaxone, any cephalosporin, or a severe allergic reaction to any other beta-lactam antibacterial agent (e.g., penicillin).

Use is also prohibited in premature neonates and hyperbilirubinemic neonates (due to the risk of bilirubin-related brain injury). Additionally, neonates (le 28 days) who require calcium-containing intravenous solutions (including parenteral nutrition) are contraindicated due to the risk of ceftriaxone-calcium precipitation.


Age and Condition-Based Restrictions

Adults, adolescents, and pediatric patients (over 15 days old) are generally eligible. Use in older adults typically requires no dosage adjustment if kidney and liver function are satisfactory.

Patients with severe impairment of both renal and hepatic function require caution, and the total daily dose is officially restricted. Use during pregnancy and lactation is generally restricted to situations where the medicine is considered clearly needed, acknowledging that it is secreted into breast milk at low concentrations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Nilson (Ceftriaxone) is defined by several regulatory constraints concerning co-administration and specific patient populations.

Intravenous Co-Administration and Physical Incompatibility

A critical restriction involves calcium-containing intravenous solutions. Ceftriaxone must not be mixed or administered simultaneously with any calcium-containing solution, including Total Parenteral Nutrition (TPN), due to the physical risk of precipitation. This incompatibility is a formal contraindication for intravenous co-administration with calcium in all neonates (up to 28 days of age) because of the documented risk of fatal ceftriaxone-calcium precipitation in the lungs and kidneys. For patients older than 28 days, sequential administration is permissible only if the infusion lines are thoroughly flushed with a compatible liquid before and after administration.

Pharmacodynamic and Clearance Interactions

Co-administration with anticoagulants (such as Warfarin) is associated with an officially documented increased risk of bleeding (hypoprothrombinaemia). Furthermore, Ceftriaxone may adversely affect the efficacy of oral hormonal contraceptives. The regulatory label notes that clearance is reduced in patients with combined severe renal and hepatic insufficiency, which is an exposure-modifying interaction officially requiring dosage consideration. The drug does not alter the elimination of Probenecid and has not been shown to cause a disulfiram-like reaction with alcohol.

Mechanism of Action

Irreversible Blockade of Bacterial Cell Wall Production

Nilson's active molecule, Ceftriaxone, acts as an irreversible inhibitor of Penicillin-Binding Proteins (PBPs), which are bacterial transpeptidase enzymes essential for building the rigid peptidoglycan layer of the cell wall. The drug's beta-lactam ring covalently binds to and permanently disables these enzymes, thereby blocking the final cross-linking step in the cell wall assembly pathway. This molecular inhibition initiates a cascade of events leading directly to the destruction of the bacterial structure.

The Bactericidal Cascade and Pathogen Destruction

The formation of a defective and unstable cell wall cannot withstand the high internal pressure of the bacterial cell, which often leads to the dysregulation of bacterial autolytic enzymes. This results in immediate cell lysis (rupture) and death of the susceptible bacteria. This process defines a bactericidal mechanism where it actively kills susceptible pathogens. The systemic destruction of susceptible bacterial pathogens produces the resulting physiological effect of a reduced microbial population within the systemic environment.

Mechanistic Limitations

The drug's inhibitory action is constrained when bacteria develop beta-lactamases, enzymes that chemically destroy the drug molecule before it can reach its PBP target. Mutations in the PBP structure can also reduce the drug's binding affinity, preventing the critical inhibitory action and resulting in a failure to achieve the intended physiological effect of pathogen destruction.

Dosage and Administration Information

How to Use Nilson (Ceftriaxone)

The usage of Nilson is defined by a strict set of administration rules for this injectable medicine, following established prescribing information. The active ingredient, Ceftriaxone, is administered via a parenteral route, specifically as an Intravenous (IV) injection or infusion, or as a deep Intramuscular (IM) injection.

Official Administration and Dosing

The medicine is supplied as a sterile lyophilized powder that requires reconstitution with a specified sterile diluent immediately before use. For IM administration, the diluent may contain lidocaine to minimize local discomfort; this solution must not be administered intravenously.

The standard adult dose ranges from 1 g to 2 g and is typically administered once every 24 hours (q24h) for routine infections. For severe systemic infections, the dose may be increased up to a maximum of 4 g daily, often delivered in equally divided doses every 12 hours (q12h). Treatment duration is not open-ended and usually spans a course of 4 to 14 days, depending on the targeted condition.

Procedural and Population Constraints

The instructions carry several key procedural conditions. Nilson must not be mixed with or administered concurrently in the same line as calcium-containing IV solutions (including TPN) due to the risk of precipitation. Furthermore, specific dose modifications are required for certain patient populations: in patients with combined severe renal and hepatic dysfunction, the total daily dose should not exceed 2 g.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nilson (Ceftriaxone)

The clinical evaluation of Nilson's active ingredient, Ceftriaxone, has been the focus of research, primarily through Randomized Controlled Trials (RCTs), systematic reviews, and large-scale observational studies. This overview describes the structure of the evidence for the specific clinical situations where the medicine has been studied, remaining neutral and avoiding any clinical recommendations.


Evidence for Use in Severe Systemic Infections (Bacterial Meningitis and Septicemia)

Research has explored the use of Ceftriaxone in conditions associated with acute or disruptive episodes, specifically severe infections affecting the central nervous system (meningitis) and bloodstream infections (septicemia). In studies of bacterial meningitis, researchers focused on tracking outcomes related to all-cause mortality and long-term functional status, particularly the incidence of neurological impairment. Studies monitored clinical outcomes, and the findings describe the patterns observed in the studies.


Evidence for Use in Hospital-Required Infections (Pneumonia and Complicated UTIs)

A substantial body of research has explored Ceftriaxone's role in managing conditions marked by physiological strain such as severe community-acquired pneumonia (CAP) and complicated urinary tract infections (UTIs). Comparative studies report how symptoms evolved in the observed populations, and findings indicate patterns related to the outcomes observed with other established antibiotic regimens. While studies report outcomes related to microbiological clearance, some retrospective observational data suggest its use was associated with certain re-infection patterns caused by specific organisms in some study groups.


What Remains Uncertain and Areas for Future Research

While the research base for Ceftriaxone is substantial, certainty remains low in several specific areas, leading to ongoing research:

  • Optimal Dosing: Evidence quality varies across studies regarding the optimal dosing frequency for specific infections, particularly in critically ill patients who may clear the drug faster.
  • Resistance: Research is ongoing to track the patterns of antimicrobial resistance. Data show patterns related to some bacterial strains that have developed resistance to Ceftriaxone, which limits its applicability in those specific cases and calls for continuous monitoring.

Key Studies & References

  1. Antimicrobial prophylaxis for surgery: NICE guideline

Frequently Asked Questions (FAQ)

Common questions about Nilson (FAQ)

Q: How long does it typically take to feel the effects of Nilson?

Patient information indicates that for systemic infections, clinical improvement often begins within the first few days of starting therapy. The duration of treatment, which is typically short, is determined by a qualified healthcare professional based on the type and severity of the infection.

Q: How long does Nilson stay in your system?

The elimination of Nilson is described in official pharmacokinetic data. The half-life, which is the time it takes for half of the drug to be cleared from the bloodstream, typically ranges from 5.8 to 8.7 hours. Complete removal of the drug from the body will take several half-lives.

Q: Can Nilson be used for things other than its main prescribed purpose?

Regulatory documents define the specific bacterial infections for which Nilson is approved to treat. Official product information does not describe or address the use of this medicine for conditions other than those formally indicated on the label.

Q: What is Nilson's safety classification during pregnancy, according to official sources?

Different regulatory bodies have assigned specific classifications for Nilson. For example, the US FDA assigned a Pregnancy Category B classification. Use during pregnancy is officially restricted to situations where the medicine is considered clearly necessary.

Q: Can Nilson cause stomach issues like nausea or heartburn?

Gastrointestinal events have been reported in the official safety profile. These include common reactions like nausea and vomiting, as well as symptoms like abdominal cramps and heartburn.

Q: Are there long-term effects of taking Nilson that studies have looked into?

Nilson is typically administered as a short course lasting 4 to 14 days. Because of this short duration of treatment, studies primarily focus on the long-term functional status of patients after the infection is treated, rather than effects related to long-term, continuous drug exposure.

Q: Can Nilson be split or crushed?

Nilson is supplied as a powder which is typically reconstituted into a solution for intravenous (IV) or intramuscular (IM) injection. Because of its parenteral route of administration, the drug is not an oral tablet or capsule and cannot be split or crushed.

Q: What is the mechanism of action of Nilson explained in simple terms?

The medicine works by physically attaching to and blocking the enzymes bacteria need to build their protective outer cell wall. This action causes the bacterial cells to rupture and die. This process defines the drug's classification as bactericidal, meaning it actively kills susceptible bacteria.

Q: Does Nilson cause weight gain?

Official regulatory documents do not list weight gain as a common or direct side effect of Nilson. However, unusual weight loss has been listed as a rare, serious adverse reaction that requires monitoring.

Q: Does Nilson affect sleep?

Drowsiness or sleepiness is reported as a neurological adverse reaction in official safety information. This is one of the central nervous system (CNS) effects that medical professionals monitor during treatment.

Q: What happens if I miss a dose of Nilson?

Patient guidance for a missed dose is included in official patient information. Patient guidance advises that if a dose is missed, it should generally be administered as soon as it is remembered. If it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular schedule should be continued without using a double amount.

Q: Are there any specific foods or drinks to avoid while taking Nilson?

The active ingredient itself does not have reported food restrictions. However, the lidocaine diluent, which is sometimes used for intramuscular injection, may interact with certain substances that affect liver enzymes.

Q: Will Nilson change my mood?

Changes in emotional state, such as feeling anxious, nervous, or confused, have been reported as adverse reactions. These symptoms fall under neurological effects and are monitored during treatment.

Q: What is the shelf life of Nilson once the bottle is opened?

Nilson is supplied as a powder that is reconstituted into a solution before use. Once reconstituted, official stability data indicates that the solution is physically and chemically stable for 24 hours at room temperature, or up to 3 days when refrigerated.

Q: Is it normal to feel tired in the first few days of taking Nilson?

A general feeling of tiredness or unusual weakness has been reported as an adverse reaction in clinical trial data. These effects are reported in clinical data and are part of the safety profile monitored by healthcare professionals.

Q: What are the official warnings about driving or operating machinery while taking Nilson?

Because the medicine may cause central nervous system (CNS) side effects such as dizziness or sleepiness (somnolence), official product information includes a general cautionary statement regarding the performance of tasks requiring concentration. This includes driving or operating heavy machinery.

Q: What happens if you suddenly stop taking Nilson?

Official patient counseling describes that incomplete treatment of the underlying infection is a potential factor when the medication course is interrupted. Furthermore, this practice is associated with increasing the risk of bacteria developing resistance to the antibiotic.

Q: Is Nilson a habit-forming medicine?

Nilson is a cephalosporin antibiotic. It is not classified as a controlled substance or narcotic by regulatory agencies.

Q: Is it true that Nilson can cause headaches?

Headache is listed as an adverse reaction in official regulatory documents. It is classified as an uncommon reaction, meaning it is reported to affect 0.1% to 1% of patients.

Q: What is the full list of inactive ingredients in Nilson?

The full list of inactive ingredients, as well as the active component Ceftriaxone sodium, is detailed in the official prescribing information. This information is typically found in the Description or Components section of the regulatory label.

Q: What is the risk of overdose with Nilson?

Official patient safety literature addresses the risk of overdose. Taking an excessive amount may result in very high levels of the drug in the body. Reported signs include sleepiness, nausea, vomiting, and tremors.

Q: Does Nilson affect blood sugar levels?

Official patient information notes that some formulations of the medicine may contain sugar. Because of this, official information advises that individuals with high blood sugar or diabetes may need to discuss this with a healthcare provider regarding appropriate glucose monitoring.

Q: What is the difference between Nilson and a placebo in clinical trials?

Nilson contains the active ingredient Ceftriaxone, which works by destroying the bacterial cell wall (a bactericidal effect). A placebo, used for comparison in clinical trials, is an inactive substance that has no known pharmacological effect on the body.

How should Nilson be stored and disposed of?

How to Store and Dispose of Nilotinib

The official storage and disposal guidelines for Nilotinib capsules are defined by governmental regulatory documents to ensure product stability and safety.

Storage Requirements

Storage Classification Requirement
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Excursions between 15 C and 30 C are permitted.
Child Safety Keep Nilotinib and all medicines out of the reach of children.

Stability and Disposal

If the capsule contents are mixed with applesauce for administration, the mixture must be taken immediately within 15 minutes. This prepared mixture must not be stored for future use and any unused portion must be thrown away. General instructions mandate that medicine that is out of date or no longer needed should be safely disposed of.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nilson found in:

A-Z Index: